Keywords: ADCC; antibody-dependent cell-mediated cytotoxicity; AKT; protein kinase B; ATP; adenosine triphosphate; cfDNA; circulating free DNA; CISH; chromogenic in-situ hybridization; CTC; circulating tumor cells; EGFR; epithelial growth factor receptor; EMT; epit
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Ado-trastuzumab emtansine; CNS metastasis; HER2; Lapatinib; Radiation;
Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers- an overview
Keywords: Antibody-drug conjugates; Monoclonal antibodies; Anticancer; Drug resistance; Solid tumors; Hematological tumors; ADC; Antibody-Drug Conjugate; ALCL; Anaplastic Large Cell Lymphoma; ALL; Acute Lymphoblastic Leukemia; AML; Acute Myeloid Leukemia; BCMA; B C
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression
Keywords: SYD985; T-DM1; Antibody-drug conjugate; Ovarian serous carcinoma; HER2; Ado-trastuzumab emtansine;
Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine
Keywords: Antibody-drug conjugate; Ado-trastuzumab emtansine; Two-dimensional liquid chromatography; Multiple heart-cutting; Comprehensive;
Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's Office of Pharmaceutical Quality
Keywords: ADF; abuse deterrent formulation; API; active pharmaceutical ingredient; T-DM1; Ado-Trastuzumab Emtansine; ADC; antibody-drug conjugate; CDER; center for drug evaluation and research; CBRN/EID; chemical, biological, radiological/nuclear and emerging infec
HER2 aberrations in cancer: Implications for therapy
Keywords: Human epidermal growth factor 2; Cancer; Target therapy; Trastuzumab; Lapatinib; Ado-trastuzumab emtansine; Pertuzumab; Afatinib;
Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability
Keywords: Breast cancer; HER2; Ado-trastuzumab emtansine; T-DM1; Toxicology; Antibody-drug conjugates;